Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC March 18, 2026
- AI CellVoyager Agent Turns Single‑Cell RNA‑seq Data into Continuous Hypothesis Generation March 18, 2026
- Ferroptosis-Nanoparticles Turn Prostate Tumors Hot: Docetaxel + Light Wakes Immunity March 18, 2026
- SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision March 18, 2026
Protac NP18: A New Hope for Prostate Cancer Treatment
/in Preclinical Research, PROTACs/by MaxAI designed cancer drug gets FDA approval for clinical trials
/in Artificial Intelligence, Not PCa related/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/in Observational, Retrospective studies/by MaxNodularin-R Enhances Abiraterone’s Effectiveness Against Castration-Resistant Prostate Cancer In Vivo
/in Preclinical Research/by MaxOlaparib’s Effectiveness Duration in Prostate Cancer Treatment
/in Post-hoc/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by Max